menu
    • menu
    [{"orgOrder":0,"company":"Chimagen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"1A46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chimagen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chimagen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chimagen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Chimagen Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Acquisition","leadProduct":"CMG1A46","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Chimagen Biosciences","amount2":0.84999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.84999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Chimagen Biosciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Chimagen Biosciences \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals by Chimagen Biosciences

    Menu

    Chimagen Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chimagen Biosciences

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Chimagen Biosciences

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMG1A46

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : GSK

                            Deal Size : $850.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            GSK to Acquire Chimagen’s CMG1A46 for Autoimmune Disease

                            Details : Through the acquisition, GSK plans to develop and commercialize CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $300.0 million

                            October 29, 2024

                            Lead Product(s) : CMG1A46

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : GSK

                            Deal Size : $850.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chimagen Biosciences

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Chimagen Biosciences

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 1A46

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Mali...

                            Details : 1A46 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 27, 2022

                            Lead Product(s) : 1A46

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth